PV
MCID: PLY001
MIFTS: 76

Polycythemia Vera (PV)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Polycythemia Vera

MalaCards integrated aliases for Polycythemia Vera:

Name: Polycythemia Vera 57 12 76 53 25 59 75 37 29 13 55 6 44 15 38 63 40 73
Pv 57 53 25 59 75
Polycythemia Rubra Vera 57 53 59 75
Prv 57 53 25 75
Osler-Vaquez Disease 25 59 75
Primary Polycythemia 53 25
Acquired Primary Erythrocytosis 59
Polycythemia Rubra Vera; Prv 57
Proliferative Polycythaemia 12
Polycythemia Vera, Somatic 57
Polycythaemia Rubra Vera 12
Polycythemia Ruba Vera 25
Osler-Vaquez Syndrome 12
Vaquez Disease 59

Characteristics:

Orphanet epidemiological data:

59
polycythemia vera
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
mean age at onset 57-60 years
children rarely develop the disorder
familial cases are rare and show incomplete penetrance
distinct disorder from familial erythrocytosis (ecyt1, )


HPO:

32

Classifications:



Summaries for Polycythemia Vera

NIH Rare Diseases : 53 Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis). Affected people may also have excess white blood cells and platelets. Conditions where the body makes too many of these cells are known as myeloproliferative neoplasms. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins deep in the arms and the legs, it is known as deep vein thrombosis (DVT). A DVT can sometimes travel through the blood stream to the lungs, which can cause a pulmonary embolism and is very dangerous. A blood clot could also travel to the heart or brain, which leads to an increased risk for heart attack or stroke. Most cases of PV are not inherited and are acquired during a person�??s lifetime. PV is more common as a person ages, and it typically presents for the first time around 60-years-old. PV occurs more frequently in men than it does in women. The condition has been associated with mutations in the JAK2 and TET2 genes. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner.

MalaCards based summary : Polycythemia Vera, also known as pv, is related to erythrocytosis, familial, 1 and polycythemia. An important gene associated with Polycythemia Vera is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zinc and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include myeloid, heart and bone, and related phenotypes are respiratory insufficiency and splenomegaly

Disease Ontology : 12 A primary polycythemia and a myeloproliferative neoplasm characterized by erythroid hyperplasia, myeloid leukocytosis, thrombocytosis, and splenomegaly.

Genetics Home Reference : 25 Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream. Affected individuals may also have excess white blood cells and blood clotting cell fragments called platelets. These extra cells and platelets cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain.

OMIM : 57 Polycythemia vera, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients (Cario, 2005). PV is distinct from the familial erythrocytoses (see, e.g., ECYT1, 133100), which are caused by inherited mutations resulting in hypersensitivity of erythroid progenitors to hormonal influences or increased levels of circulating hormones, namely erythropoietin (EPO; 133170) (Prchal, 2005). (263300)

UniProtKB/Swiss-Prot : 75 Polycythemia vera: A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.

PubMed Health : 63 About polycythemia vera: Polycythemia vera (POL-e-si-THEE-me-ah VAY-rah or VE-rah), or PV, is a rare blood disease in which your body makes too many red blood cells.The extra red blood cells make your blood thicker than normal. As a result, blood clots can form more easily. These clots can block blood flow through your arteries and veins, which can cause a heart attack or stroke.Thicker blood also doesn't flow as quickly to your body as normal blood. Slowed blood flow prevents your organs from getting enough oxygen, which can cause serious problems, such as angina (an-JI-nuh or AN-juh-nuh) and heart failure. (Angina is chest pain or discomfort.)

Wikipedia : 76 Polycythemia vera is an uncommon neoplasm in which the bone marrow makes too many red blood cells. It... more...

Related Diseases for Polycythemia Vera

Diseases related to Polycythemia Vera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 erythrocytosis, familial, 1 32.8 EPO EPOR IL3 JAK2 THPO
2 polycythemia 32.7 CD177 EPO EPOR IL3 JAK1 JAK2
3 primary polycythemia 32.3 CD177 EPO EPOR IL3 JAK1 JAK2
4 myeloproliferative neoplasm 31.6 H19 JAK2 JAK3 KIT MPL PDGFRA
5 essential thrombocythemia 31.4 CD177 EPO EPOR IL3 JAK2 MPL
6 myelofibrosis 31.0 CD177 EPO HMGA2 IL3 JAK1 JAK2
7 thrombocytosis 31.0 EPO IL3 JAK2 MPL TET2 THPO
8 splenomegaly 30.9 EPO JAK2 MPL
9 myeloid leukemia 30.9 IL3 JAK2 KIT TET2
10 acquired polycythemia 30.9 EPO EPOR JAK2
11 leukemia, acute myeloid 30.3 IL3 JAK2 KIT KITLG MPL STAT3
12 gastrointestinal stromal tumor 30.2 KIT KITLG PDGFRA PDGFRB
13 pancytopenia 30.1 EPO IL3 MPL THPO
14 deficiency anemia 30.1 EPO EPOR IL3 THPO
15 refractory anemia 30.1 EPO IL3 JAK2 MPL TET2
16 chronic myelomonocytic leukemia 30.0 JAK2 KIT PDGFRB TET2
17 megakaryocytic leukemia 30.0 IL3 JAK2 JAK3 KITLG THPO
18 hepatitis c 30.0 JAK1 SOCS3 STAT3 TYK2
19 hypereosinophilic syndrome 29.9 IL3 KIT PDGFRA PDGFRB
20 mastocytosis 29.8 KIT KITLG PDGFRA PDGFRB TET2
21 systemic mastocytosis 29.7 JAK2 KIT KITLG PDGFRA PDGFRB TET2
22 myelodysplastic syndrome 29.7 EPO EPOR IL3 JAK2 KIT KITLG
23 leukemia, chronic myeloid 29.5 CD177 EPO H19 IL3 JAK2 KIT
24 psoriasis 1 11.7
25 budd-chiari syndrome 11.7
26 erythromelalgia 11.6
27 aquagenic pruritus 11.6
28 pulmonary valve stenosis 11.5
29 pemphigus vulgaris, familial 11.4
30 persistent vegetative state 11.4
31 hemoglobin, high altitude adaptation 11.3
32 psoriasis 14, pustular 11.2
33 porphyria variegata 11.0
34 psoriasis 2 11.0
35 psoriasis 7 11.0
36 psoriasis 11 11.0
37 psoriasis 13 11.0
38 thrombosis 10.8
39 leukemia 10.7
40 lymphocytic leukemia 10.4
41 lymphoma 10.4
42 thrombocytopenia 10.3
43 pernicious anemia 10.3
44 myocardial infarction 10.3
45 ischemia 10.3
46 subacute myeloid leukemia 10.3 JAK2 TET2
47 malaria 10.3
48 pemphigus foliaceus 10.3
49 folic acid deficiency anemia 10.3 EPO TET2 THPO
50 retinitis pigmentosa and erythrocytic microcytosis 10.3 EPO IL3 JAK2

Graphical network of the top 20 diseases related to Polycythemia Vera:



Diseases related to Polycythemia Vera

Symptoms & Phenotypes for Polycythemia Vera

Symptoms via clinical synopsis from OMIM:

57
Abdomen Spleen:
splenomegaly

Cardiovascular Vascular:
cerebral ischemia
budd-chiari syndrome
thrombosis
thromboembolic events

Abdomen Gastrointestinal:
gastrointestinal bleeding

Laboratory Abnormalities:
normal or decreased serum erythropoietin (epo, )
increased prv-1 mrna
erythroid colony-forming units show spontaneous growth in the absence of epo
normal arterial oxygen saturation

Hematology:
thrombocytopenia
thrombocytosis
leukocytosis
increased hematocrit
increased red blood cell mass
more
Neurologic Central Nervous System:
cerebral ischemia
cerebral hemorrhage

Cardiovascular Heart:
myocardial ischemia


Clinical features from OMIM:

263300

Human phenotypes related to Polycythemia Vera:

59 32 (show all 39)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
2 splenomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0001744
3 hepatomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0002240
4 portal hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0001409
5 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
6 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
7 angina pectoris 59 32 hallmark (90%) Very frequent (99-80%) HP:0001681
8 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
9 pulmonary embolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0002204
10 myelodysplasia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002863
11 pruritus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000989
12 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
13 vertigo 59 32 hallmark (90%) Very frequent (99-80%) HP:0002321
14 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
15 epistaxis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000421
16 bruising susceptibility 59 32 hallmark (90%) Very frequent (99-80%) HP:0000978
17 gingival bleeding 59 32 hallmark (90%) Very frequent (99-80%) HP:0000225
18 acute leukemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002488
19 stroke 59 32 occasional (7.5%) Occasional (29-5%) HP:0001297
20 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
21 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
22 tinnitus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000360
23 intermittent claudication 59 32 occasional (7.5%) Occasional (29-5%) HP:0004417
24 myelofibrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0011974
25 budd-chiari syndrome 59 32 occasional (7.5%) Occasional (29-5%) HP:0002639
26 portal vein thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0030242
27 hypertension 59 Very frequent (99-80%)
28 thromboembolism 32 HP:0001907
29 abnormal thrombosis 32 HP:0001977
30 thrombocytopenia 32 HP:0001873
31 venous thrombosis 59 Occasional (29-5%)
32 cerebral ischemia 32 HP:0002637
33 thrombocytosis 32 HP:0001894
34 leukocytosis 32 HP:0001974
35 cerebral hemorrhage 32 HP:0001342
36 increased megakaryocyte count 32 HP:0005513
37 increased hematocrit 32 HP:0001899
38 increased red blood cell mass 32 HP:0001898
39 increased hemoglobin 32 HP:0001900

GenomeRNAi Phenotypes related to Polycythemia Vera according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in HMC1.1 cells GR00105-A-0 8.8 JAK1 JAK3 KIT

MGI Mouse Phenotypes related to Polycythemia Vera:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CD177 EPO EPOR JAK1 JAK2 JAK3
2 cellular MP:0005384 10.35 EPO EPOR JAK2 JAK3 KIT KITLG
3 immune system MP:0005387 10.31 CD177 EPO EPOR JAK1 JAK2 JAK3
4 growth/size/body region MP:0005378 10.26 EPOR JAK1 JAK2 KIT KITLG MPL
5 cardiovascular system MP:0005385 10.25 EPO EPOR JAK1 KIT KITLG PDGFRA
6 homeostasis/metabolism MP:0005376 10.25 EPO EPOR JAK1 JAK2 KIT KITLG
7 embryo MP:0005380 10.21 EPO EPOR JAK2 KIT KITLG MPL
8 endocrine/exocrine gland MP:0005379 10.15 JAK1 JAK2 JAK3 KIT KITLG PDGFRA
9 mortality/aging MP:0010768 10.1 EPO EPOR JAK1 JAK2 JAK3 KIT
10 digestive/alimentary MP:0005381 10.07 JAK3 KIT KITLG PDGFRA PDGFRB SOCS3
11 integument MP:0010771 10.02 EPO JAK1 JAK2 KIT KITLG PDGFRA
12 liver/biliary system MP:0005370 9.97 EPO EPOR JAK1 JAK2 KIT KITLG
13 normal MP:0002873 9.85 EPO EPOR JAK1 JAK2 KIT PDGFRA
14 respiratory system MP:0005388 9.5 EPO EPOR JAK1 KIT PDGFRA SOCS3
15 skeleton MP:0005390 9.32 EPO JAK1 JAK2 KIT KITLG PDGFRA

Drugs & Therapeutics for Polycythemia Vera

PubMedHealth treatment related to Polycythemia Vera: 63

Polycythemia vera (PV) doesn't have a cure. However, treatments can help control the disease and its complications. PV is treated with procedures, medicines, and other methods. You may need one or more treatments to manage the disease.

Drugs for Polycythemia Vera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6
2
Lactitol Investigational Phase 4 585-86-4 3871
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
5
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
6
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
7
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
9
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
10
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
11
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
12 Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
13
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
14
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
15
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
18
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
21
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
22
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
23
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
24
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
25
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
26
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
27 tannic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable
28
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
29
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
30
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
31
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
32
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
33 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
34 Anesthetics, Dissociative Phase 3
35 Anesthetics, General Phase 3
36 Excitatory Amino Acid Antagonists Phase 3
37 Excitatory Amino Acids Phase 3
38 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
39 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
40 Anesthetics, Intravenous Phase 3
41 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
42 Anesthetics Phase 3
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
4 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
5 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
6 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Completed NCT01243944 Phase 3 ruxolitinib tablets
7 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
8 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
9 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
10 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
11 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
12 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
13 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
14 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
15 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
19 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
20 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
24 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
25 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
26 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
27 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
28 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
29 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Not yet recruiting NCT03755518 Phase 3 FEDRATINIB
30 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
31 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
32 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
33 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
34 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
35 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
36 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
37 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
38 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
39 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
40 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
41 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
42 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
43 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
44 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)
45 Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT00726232 Phase 2 Ruxolitinib
46 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib
47 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
48 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib
49 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT01236638 Phase 2 Momelotinib
50 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT00935987 Phase 1, Phase 2 CYT387

Search NIH Clinical Center for Polycythemia Vera

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polycythemia vera

Genetic Tests for Polycythemia Vera

Genetic tests related to Polycythemia Vera:

# Genetic test Affiliating Genes
1 Polycythemia Vera 29 JAK2

Anatomical Context for Polycythemia Vera

MalaCards organs/tissues related to Polycythemia Vera:

41
Myeloid, Heart, Bone, Bone Marrow, Brain, Lung, T Cells

Publications for Polycythemia Vera

Articles related to Polycythemia Vera:

(show top 50) (show all 2131)
# Title Authors Year
1
Genetic Transformation of Cotton with the Harpin-Encoding Gene hpaXoo of Xanthomonas oryzae pv. oryzae and Evaluation of Resistance Against Verticillium Wilt. ( 30543078 )
2019
2
The impact of air pollutant deposition on solar energy system efficiency: An approach to estimate PV soiling effects with the Community Multiscale Air Quality (CMAQ) model. ( 30243165 )
2019
3
Tianeptine antagonizes the reduction of PV+ and GAD67 cells number in dorsal hippocampus of socially isolated rats. ( 30367961 )
2019
4
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. ( 29226426 )
2018
5
Impact of hydroxycarbamide and interferon-I+ on red cell adhesion and membrane protein expression in polycythemia vera. ( 29599206 )
2018
6
Serum ferritin as a biomarker of polycythemia vera? ( 29765288 )
2018
7
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. ( 29734070 )
2018
8
Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. ( 29955128 )
2018
9
Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. ( 29437189 )
2018
10
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ( 29427319 )
2018
11
Polycythemia vera treatment algorithm 2018. ( 29321547 )
2018
12
The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology. ( 29717365 )
2018
13
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. ( 29335456 )
2018
14
Safety and efficacy of combination therapy of interferon-I+2 and ruxolitinib in polycythemia vera and myelofibrosis. ( 29932310 )
2018
15
The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. ( 29885533 )
2018
16
Polycythemia vera and essential thrombocythemia: algorithmic approach. ( 29194068 )
2018
17
Bone marrow findings in blast phase of polycythemia vera. ( 29285580 )
2018
18
Cytoreductive treatment patterns among US veterans with polycythemia vera. ( 29728092 )
2018
19
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. ( 29181548 )
2018
20
A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera. ( 29941837 )
2018
21
Congenital methemoglobinemia misdiagnosed as polycythemia vera: Case report and review of literature. ( 29721250 )
2018
22
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. ( 29622658 )
2018
23
Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. ( 29290171 )
2018
24
Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera. ( 29611054 )
2018
25
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. ( 29804268 )
2018
26
Unmasking and aggravation of polycythemia vera by canagliflozin. ( 29888479 )
2018
27
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. ( 29625320 )
2018
28
Improvement in Ulcerative Necrobiosis Lipoidica After Janus Kinase-Inhibitor Therapy for Polycythemia Vera. ( 29800055 )
2018
29
Distinctive CD8<sup>+</sup> T cell and MHC class I signatures in polycythemia vera patients. ( 29789880 )
2018
30
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. ( 28956263 )
2018
31
Increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera. ( 29660912 )
2018
32
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. ( 29556018 )
2018
33
Masked polycythemia Vera (mPV): Results of an international study. ( 29634089 )
2018
34
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 30521827 )
2018
35
Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera. ( 29984752 )
2018
36
Ischemic colitis caused by polycythemia vera: A case report and literature review. ( 30233723 )
2018
37
Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. ( 30305475 )
2018
38
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). ( 29246923 )
2018
39
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ( 29313725 )
2018
40
Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. ( 29488167 )
2018
41
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( 30281843 )
2018
42
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. ( 30291232 )
2018
43
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎. ( 30502854 )
2018
44
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? ( 30545998 )
2018
45
Safety of Therapeutic Plasma Exchange for the Treatment of Guillain-Barré Syndrome in Polycythemia Vera. ( 30379740 )
2018
46
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. ( 29685167 )
2018
47
Inhibition of herpes simplex virus 1 (HSV-1) and poliovirus (PV-1) by bacteriocins from lactococcus lactis subsp. lactis and enterococcus durans strains isolated from goat milk. ( 28668682 )
2018
48
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. ( 28935991 )
2018
49
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. ( 29713873 )
2018
50
A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. ( 29534684 )
2018

Variations for Polycythemia Vera

UniProtKB/Swiss-Prot genetic disease variations for Polycythemia Vera:

75
# Symbol AA change Variation ID SNP ID
1 JAK2 p.Val617Phe VAR_032697 rs77375493

ClinVar genetic disease variations for Polycythemia Vera:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
3 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh37 Chromosome 1, 65312347: 65312347
4 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh38 Chromosome 1, 64846664: 64846664
5 JAK2 NM_004972.3(JAK2): c.2571+5A> C single nucleotide variant not provided rs775085241 GRCh38 Chromosome 9, 5081866: 5081866
6 JAK2 NM_004972.3(JAK2): c.2571+5A> C single nucleotide variant not provided rs775085241 GRCh37 Chromosome 9, 5081866: 5081866

Expression for Polycythemia Vera

Search GEO for disease gene expression data for Polycythemia Vera.

Pathways for Polycythemia Vera

Pathways related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 CD177 IL3 JAK1 JAK2 JAK3 KIT
2
Show member pathways
13.94 EPOR IL3 JAK1 JAK2 JAK3 KIT
3
Show member pathways
13.82 EPOR IL3 JAK1 JAK2 JAK3 KIT
4
Show member pathways
13.74 EPO EPOR IL3 JAK2 JAK3 KIT
5
Show member pathways
13.58 IL3 JAK1 JAK2 JAK3 KIT KITLG
6
Show member pathways
13.49 EPOR IL3 JAK1 JAK2 JAK3 KIT
7
Show member pathways
13.43 IL3 JAK1 JAK2 JAK3 KIT KITLG
8
Show member pathways
13.43 EPO EPOR IL3 JAK1 JAK2 JAK3
9
Show member pathways
13.39 EPOR IL3 KIT KITLG PDGFRA PDGFRB
10
Show member pathways
13.39 CD177 IL3 JAK1 JAK2 JAK3 MPL
11
Show member pathways
13.37 IL3 JAK2 KIT KITLG PDGFRA PDGFRB
12
Show member pathways
13.35 EPOR IL3 KIT KITLG PDGFRA PDGFRB
13
Show member pathways
13.13 IL3 KIT KITLG PDGFRA PDGFRB THPO
14
Show member pathways
13.09 IL3 JAK1 JAK2 KIT KITLG PDGFRA
15
Show member pathways
13.02 EPO EPOR JAK2 KIT KITLG PDGFRA
16
Show member pathways
13.01 JAK1 JAK2 JAK3 PDGFRA PDGFRB STAT3
17
Show member pathways
13.01 EPO EPOR IL3 JAK1 JAK2 JAK3
18
Show member pathways
12.98 EPOR JAK1 JAK2 JAK3 PDGFRA PDGFRB
19
Show member pathways
12.95 IL3 JAK1 KIT PDGFRA PDGFRB STAT3
20
Show member pathways
12.9 JAK1 JAK2 JAK3 MPL SOCS3 STAT3
21
Show member pathways
12.89 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
22
Show member pathways
12.87 JAK1 JAK2 JAK3 PDGFRA PDGFRB STAT3
23
Show member pathways
12.72 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
24 12.72 EPO EPOR IL3 JAK1 JAK2 JAK3
25
Show member pathways
12.7 JAK1 JAK2 PDGFRA PDGFRB SOCS3 STAT3
26 12.6 HMGA2 MIR150 PDGFRA PDGFRB STAT3
27
Show member pathways
12.53 JAK1 JAK2 SOCS3 STAT3
28
Show member pathways
12.52 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
29
Show member pathways
12.51 EPOR IL3 KIT KITLG PDGFRA PDGFRB
30 12.48 JAK1 JAK3 PDGFRA PDGFRB
31
Show member pathways
12.46 KIT KITLG PDGFRA PDGFRB
32
Show member pathways
12.46 JAK1 JAK2 JAK3 STAT3
33
Show member pathways
12.46 IL3 JAK1 JAK2 JAK3 STAT3 TYK2
34
Show member pathways
12.38 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
35
Show member pathways
12.37 JAK1 JAK2 STAT3 TYK2
36 12.37 IL3 JAK1 JAK2 JAK3 KIT KITLG
37 12.36 JAK1 JAK3 STAT3 TYK2
38
Show member pathways
12.34 JAK1 JAK2 JAK3 STAT3 TYK2
39
Show member pathways
12.33 JAK1 JAK2 STAT3 TYK2
40
Show member pathways
12.32 IL3 JAK1 KIT KITLG PDGFRA PDGFRB
41
Show member pathways
12.23 IL3 JAK1 JAK2 JAK3
42
Show member pathways
12.22 JAK1 PDGFRA PDGFRB STAT3
43
Show member pathways
12.21 JAK1 JAK2 JAK3 SOCS3 STAT3
44 12.21 JAK2 KIT KITLG PDGFRA PDGFRB SOCS3
45
Show member pathways
12.2 IL3 JAK1 JAK2 KITLG STAT3 THPO
46 12.2 IL3 KITLG PDGFRB STAT3 THPO
47
Show member pathways
12.19 JAK1 JAK2 JAK3 STAT3 TYK2
48 12.18 JAK1 JAK2 JAK3 STAT3
49
Show member pathways
12.18 EPO EPOR IL3 JAK1 JAK2 KIT
50 12.15 JAK1 SOCS3 STAT3 TYK2

GO Terms for Polycythemia Vera

Biological processes related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.98 JAK2 KIT PDGFRA PDGFRB
2 positive regulation of cell proliferation GO:0008284 9.97 EPO IL3 JAK2 KIT KITLG PDGFRA
3 negative regulation of signal transduction GO:0009968 9.96 KIT PDGFRA PDGFRB SOCS3
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.92 JAK2 KIT PDGFRA PDGFRB
5 male gonad development GO:0008584 9.89 KIT KITLG PDGFRB
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.89 KIT PDGFRA PDGFRB
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 IL3 JAK2 KITLG
8 cell chemotaxis GO:0060326 9.88 KIT PDGFRA PDGFRB
9 phosphatidylinositol phosphorylation GO:0046854 9.88 KIT KITLG PDGFRA PDGFRB SOCS3
10 positive regulation of MAP kinase activity GO:0043406 9.86 KIT KITLG PDGFRB
11 erythrocyte differentiation GO:0030218 9.86 EPO JAK2 JAK3 KIT
12 interleukin-12-mediated signaling pathway GO:0035722 9.85 JAK1 JAK2 TYK2
13 platelet-derived growth factor receptor signaling pathway GO:0048008 9.83 JAK2 PDGFRA PDGFRB
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.83 KIT PDGFRA PDGFRB
15 interleukin-7-mediated signaling pathway GO:0038111 9.82 JAK1 JAK3 STAT3
16 JAK-STAT cascade GO:0007259 9.82 JAK2 SOCS3 STAT3
17 embryonic hemopoiesis GO:0035162 9.79 IL3 KIT KITLG
18 interleukin-15-mediated signaling pathway GO:0035723 9.77 JAK1 JAK3 STAT3
19 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.77 JAK2 JAK3 STAT3
20 positive regulation of phospholipase C activity GO:0010863 9.76 KIT PDGFRA PDGFRB
21 MAPK cascade GO:0000165 9.76 IL3 JAK1 JAK2 JAK3 KIT KITLG
22 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.75 JAK1 JAK2 SOCS3
23 interleukin-35-mediated signaling pathway GO:0070757 9.74 JAK1 JAK2 STAT3
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 EPO IL3 JAK2 KIT SOCS3 STAT3
25 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.72 JAK2 PDGFRB
26 interleukin-23-mediated signaling pathway GO:0038155 9.72 JAK2 STAT3 TYK2
27 response to hyperoxia GO:0055093 9.71 EPO PDGFRB
28 growth hormone receptor signaling pathway GO:0060396 9.71 JAK2 STAT3
29 interleukin-9-mediated signaling pathway GO:0038113 9.71 JAK1 JAK3 STAT3
30 interleukin-6-mediated signaling pathway GO:0070102 9.71 JAK1 JAK2 SOCS3 STAT3
31 interleukin-2-mediated signaling pathway GO:0038110 9.7 JAK1 JAK3
32 regulation of JAK-STAT cascade GO:0046425 9.7 JAK2 JAK3
33 postsynapse to nucleus signaling pathway GO:0099527 9.7 JAK2 STAT3
34 tyrosine phosphorylation of STAT protein GO:0007260 9.7 JAK2 JAK3
35 enzyme linked receptor protein signaling pathway GO:0007167 9.69 JAK2 JAK3
36 retina vasculature development in camera-type eye GO:0061298 9.69 PDGFRA PDGFRB
37 interleukin-21-mediated signaling pathway GO:0038114 9.69 JAK1 JAK3 STAT3
38 ectopic germ cell programmed cell death GO:0035234 9.68 KIT KITLG
39 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.68 KITLG THPO
40 thrombopoietin-mediated signaling pathway GO:0038163 9.67 MPL THPO
41 metanephric glomerular capillary formation GO:0072277 9.67 PDGFRA PDGFRB
42 interleukin-27-mediated signaling pathway GO:0070106 9.67 JAK1 JAK2 STAT3 TYK2
43 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.66 PDGFRA PDGFRB
44 positive regulation of growth factor dependent skeletal muscle satellite cell proliferation GO:1902728 9.64 JAK2 STAT3
45 erythropoietin-mediated signaling pathway GO:0038162 9.61 EPO EPOR KIT
46 peptidyl-tyrosine phosphorylation GO:0018108 9.56 IL3 JAK1 JAK2 JAK3 KIT PDGFRA
47 cytokine-mediated signaling pathway GO:0019221 9.32 EPOR IL3 JAK1 JAK2 JAK3 KIT
48 protein phosphorylation GO:0006468 10.17 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
49 phosphorylation GO:0016310 10.1 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
50 cell proliferation GO:0008283 10.08 EPO KITLG MPL STAT3 THPO

Molecular functions related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.95 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
2 nucleotide binding GO:0000166 9.91 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
3 protein kinase activity GO:0004672 9.87 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
4 transmembrane signaling receptor activity GO:0004888 9.83 KIT MPL PDGFRA PDGFRB
5 cytokine activity GO:0005125 9.81 EPO IL3 KITLG THPO
6 protein phosphatase binding GO:0019903 9.72 JAK1 JAK3 STAT3
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.67 KIT KITLG PDGFRA PDGFRB
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 KIT PDGFRA PDGFRB
9 platelet-derived growth factor receptor binding GO:0005161 9.57 PDGFRA PDGFRB
10 platelet-derived growth factor binding GO:0048407 9.56 PDGFRA PDGFRB
11 protein tyrosine kinase activity GO:0004713 9.56 IL3 JAK1 JAK2 JAK3 KIT PDGFRA
12 type 1 angiotensin receptor binding GO:0031702 9.54 JAK2 TYK2
13 CCR5 chemokine receptor binding GO:0031730 9.49 JAK1 STAT3
14 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRA PDGFRB
15 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.46 JAK1 JAK2 JAK3 TYK2
16 growth hormone receptor binding GO:0005131 9.43 JAK1 JAK2 TYK2
17 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 IL3 JAK1 JAK2 JAK3 KIT KITLG

Sources for Polycythemia Vera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....